MRSH 8-K
Marsh & Mclennan Companies, Inc. (MRSH)
8-K
2025-07-09
For: 2025-07-09
View Original
Added on
April 08, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________
| FORM | |||||
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| Date of report (Date of earliest event reported) | |||||
| (Exact Name of Registrant as Specified in its Charter) | ||
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
| (Address of Principal Executive Offices) | (Zip Code) | |||||||||||||||||||
| Registrant’s telephone number, including area code | |||||||||||||||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||||||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||||||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||||||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | ||||||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of exchange on which registered | ||||||||||||
| NYSE Texas | ||||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
| Emerging growth company | ||||||||
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | ☐ | |||||||
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
(d) On July 9, 2025, the board of directors (the “Board”) of Marsh & McLennan Companies, Inc. (the “Company”) appointed Bruce Broussard, age 63, as an independent member of the Board, effective immediately. The Board also appointed Mr. Broussard to its Audit Committee, having determined that he satisfies all the applicable requirements to serve on such committee, including independence standards.
As a non-management director, Mr. Broussard will be compensated as described in “Description of Compensation Arrangements for Independent Directors”, which was filed as Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024.
A copy of the Company's press release, dated July 9, 2025, announcing the appointment of Mr. Broussard is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| MARSH & McLENNAN COMPANIES, INC. | ||||||||
| By: | /s/ Connor Kuratek | |||||||
| Name: | Connor Kuratek | |||||||
| Title: | Deputy General Counsel and Corporate Secretary | |||||||
Date: July 9, 2025
3
 | Marsh McLennan 1166 Avenue of the Americas New York, New York 10036-2774 212 345 5000 www.marshmclennan.com | |||||||
| News release | Exhibit 99.1 | ||||
Media Contact: Erick Gustafson Marsh McLennan +1 202 263 7788 | Investor Contact: Jay Gelb Marsh McLennan +1 212 345 1569 | ||||
Marsh McLennan appoints Bruce Broussard to its Board of Directors
NEW YORK, July 9, 2025 — The Board of Directors of Marsh McLennan (NYSE: MMC), a global leader in risk, strategy and people, today appointed Bruce Broussard as a director, effective immediately. The Company’s Board now consists of 12 directors.
Commenting on Mr. Broussard’s appointment, H. Edward Hanway, Chair of the Company’s Board of Directors, said, “We are delighted to welcome Bruce to the Board. His appointment underscores our commitment to enriching our Board with broad industry expertise.”
John Doyle, President and CEO of Marsh McLennan, said, “Bruce is a terrific addition to Marsh McLennan’s Board. He brings a wealth of knowledge in the insurance and healthcare sectors, along with valuable leadership experience as a Chief Executive and Financial Officer, which will enhance our Board's perspective on an array of important issues.”
Mr. Broussard has over 30 years of experience leading public and private healthcare organizations. He was named President of Humana in 2011 and served as Chief Executive Officer from 2013 to 2024. Prior to that, he was Chief Executive Officer of McKesson Specialty/US Oncology. He joined US Oncology, which was acquired by McKesson Specialty, in 2000, and held various leadership roles, including Chief Financial Officer, President, Chief Executive Officer and Chairman of the Board.
Mr. Broussard also serves on the boards of directors of HP Inc., Cleveland Clinic and One Call. Additionally, he holds leadership positions in numerous advocacy organizations, including The Business Council and the American Heart Association’s CEO Roundtable. He is also the Chair of the Board of Directors of the Trust for the National Mall, a nonprofit philanthropic partner of the National Park Service dedicated to restoring and preserving the National Mall.
About Marsh McLennan
Marsh McLennan (NYSE: MMC) is a global leader in risk, strategy and people, advising clients in 130 countries across four businesses: Marsh, Guy Carpenter, Mercer and Oliver Wyman. With annual revenue of over $24 billion and more than 90,000 colleagues, Marsh McLennan helps build the confidence to thrive through the power of perspective. For more information, visit marshmclennan.com, or follow on LinkedIn and X.
1